Indacaterol/glycopyrronium bromide: Phase III data

The identical, double-blind Phase III FLIGHT 1 and 2 trials in 2,043 patients with moderate to severe COPD showed that twice-daily QVA149 met the primary endpoint in each trial of improving FEV1 AUC f...